Mid-Year 2026 Boston Life Science Report

Metropolitan Boston's life science market has been off to a slow start in the first half of 2026.

Vacancy notched a nominal decrease to 26.4%, with asking rents resting at a level $82.32 SF NNN. However, there are numerous indicators of positive activity that continue to garner support in the idea of a turnaround on the horizon.

Much of the same narrative persists: reduced tenant demand, dramatic oversupply, and concerns about reduced funding from VC/PE, NIH, and state funds continue to weigh heavily on fundamentals. This is much the same tune that has been playing for nearly a half-decade now. However, sentiment has shifted considerably. The IPO market is decidedly back open. With 7 biotech IPO’s so far this year, and an 8th planned, this would mark the greatest volume of IPOs since 2021 if the trend continues. IPOs are critical for several reasons, as they provide: capital access for the firms themselves, an assessment of risk appetite in the market, and exit windows for venture capital investors. Beyond the clear importance of capital access for the companies, the latter two reasons stimulate bullish sentiment. Biotech companies are often quite risky endeavors, offering outsized returns in exchange for investors assuming outsized risk. Investor’s interest in them therefore would indicate confidence in the sector is returning. We see this visualized in the NYSEARCA ($XBI) – which is trading at a relatively nominal 7.5% off its 2021 highs, a 127% rebound from its April 2025 low. Exit windows are critical: money invested in early stage or seed rounds generally remains locked up, capital is unable to be returned to their investors, which has a knock-on effect of preventing capital from being provided to the next generation of startups. As these exit opportunities open, capital will be recycled forward to startups that may not even exist yet.

Several life science assets traded hands, relevant details of which are available further in this report. The salient point for the life science market remains that these assets trade at significant discounts, allowing new ownership to offer more attractive rents to prospective tenants.

Further good news: funding has seemingly found a balance point. Greater Boston startups raised approximately $1 billion in January alone, reflective of one of the strongest single-month totals in years. Compounding that, speculative life science development has functionally fallen off a cliff. Life science companies with AI-attached verticals remain highly relevant, as we have observed Lila Sciences execute some of the largest net-new leases in recent quarters, continuously adding space on top of their existing footprint. It should be noted that Lila Sciences is in talks to raise an additional $2 billion, with an expected valuation of $8.5 billion (before the new money). Lila is a direct result of Flagship Pioneering, one of the leading Cambridge venture capital concerns. Lila raised $200M in seed financing just 15 short months ago, which serves to demonstrate the considerable appetite of investors for life science firms that have fully embraced AI. Hunneman Research forecasts this trend to continue.

The commercial real estate sector recovers more slowly than public markets or private valuations. However, there is no denying the discussed catalysts poise this market for a rebound. There is no doubt, there will certainly be plenty of world-class space for new market entrants over the remainder of the decade.

For more information please contact:

Mark Fallon, Director of Research & Strategy | mfallon@hunnemanre.com